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Abstract
Evidence is accumulating showing that septic acute kidney injury (AKI) is different from non-septic AKI. Specifically,
a large body of research points to apoptotic processes underlying septic AKI. Unravelling the complex and
intertwined apoptotic and immuno-inflammatory pathways at the cellular level will undoubtedly create new and
exciting perspectives for the future development (e.g., caspase inhibition) or refinement (specific vasopressor use)
of therapeutic strategies. Shock complicating sepsis may cause more AKI but also will render treatment of this
condition in an hemodynamically unstable patient more difficult. Expert opinion, along with the aggregated results
of two recent large randomized trials, favors continuous renal replacement therapy (CRRT) as preferential treatment
for septic AKI (hemodynamically unstable). It is suggested that this approach might decrease the need for
subsequent chronic dialysis. Large-scale introduction of citrate as an anticoagulant most likely will change CRRT
management in intensive care units (ICU), because it not only significantly increases filter lifespan but also better
preserves filter porosity. A possible role of citrate in reducing mortality and morbidity, mainly in surgical ICU
patients, remains to be proven. Also, citrate administration in the predilution mode appears to be safe and exempt
of relevant side effects, yet still requires rigorous monitoring. Current consensus exists about using a CRRT dose of
25 ml/kg/h in non-septic AKI. However, because patients should not be undertreated, this implies that doses as
high as 30 to 35 ml/kg/h must be prescribed to account for eventual treatment interruptions. Awaiting results
from large, ongoing trials, 35 ml/kg/h should remain the standard dose in septic AKI, particularly when shock is
present. To date, exact timing of CRRT is not well defined. A widely accepted composite definition of timing is
needed before an appropriate study challenging this major issue can be launched.
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Introduction
Continuous renal replacement therapy (CRRT) and espe-
cially continuous veno-venous hemofiltration (CVVH)
are widely used in intensive care units (ICU). However,
broad consensus or distinct recommendations with
regard to optimal use of CRRT in general, and particu-
larly in non-septic acute kidney injury (AKI) beyond
shock, are lacking. Nonetheless, interest in AKI and
blood purification techniques in this field continues to
grow as illustrated by many small studies and by an
increasing number of multicenter, randomized controlled
trials (RCTs) [1]. Regardless of ongoing clinical contro-
versy [2,3], large epidemiological studies convincingly
show that CVVH and derived techniques represent treat-
ments of choice for the management of septic shock
complicated by AKI [4]. Such epidemiological evidence is
relevant because RCTs are no longer considered to be
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provided the original work is properly cited.the absolute “gold standard” for demonstrating best
evidence in a complex ICU setting [5].
This review was designed to address the most recent
knowledge and future developments with regard to con-
tinuous and intermittent renal replacement therapy
(IRRT) that are of practical interest to ICU physicians.
New insights in the pathophysiology of septic AKI
Ample proof exists to sustain a more prominent role of
apoptosis rather than pure necrosis in the pathophysiol-
ogy of sepsis and septic shock [6]. Despite substantial
advances in elucidating the etiology of tubular apoptotic
lesions [7], studies that look for a possible key role of
apoptosis in the mechanisms of organ dysfunction in
humans have yielded conflicting results [8,9].
Apoptosis has been put forward as a major player in
septic AKI [10]. However, histopathological studies are
scarce and mostly date from before 1980 [9,11]. Kidney
biopsies from 19 consecutive patients who died from
septic shock were compared with post-mortem biopsies
taken from 8 trauma patients and 9 patients with non-
septic AKI [9].
Acute tubular apoptosis was demonstrated in septic
AKI, whereas almost no apoptosis was detected in the
non-septic AKI patients. In this study, three different
techniques to confirm apoptosis were applied: routine
microscopy, the TUNEL (Terminal-deoxynucleotidyltrans-
ferase-mediated d UTP-digoxigenin nick and labeling)
method, and activated caspase 3 labeling. The two last
techniques enabled to detect 6% apoptosis in the septic
group versus only 1% in the non-septic group (p < 0.0001).
However, some control biopsies were retrieved from
patients who died at the scene of trauma, which may have
limited the development of any type of histologic kidney
lesion. On the other hand, a subset of six other controls
consisted of out-of-hospital cardiac arrest patients
who most likely had cardiogenic shock before dying.
Therefore, the latter group may more reliably represent
non-septic-AKI, including its accompanying hemodynami-
cally related lesions. Further drawbacks of the study are
the cadaveric nature of the biopsies, which precludes inter-
pretation of potentially reversible changes that occur in
recovering patients and some control groups being histori-
cal controls.
From a theoretical point of view, necrosis results from
the additive effect of a number of independent biochem-
ical events that are activated by severe depletion of cell
energy stores. In contrast, the process of apoptosis fol-
lows a coordinated, predictable, and predetermined
pathway. These biochemical differences between apopto-
sis and necrosis have important therapeutic implications.
Once a cell has been severely injured, necrosis is diffi-
cult to prevent whilst the apoptotic pathway can be
modulated to maintain cell viability [12]. Theoretically,
the components of the apoptotic pathway that could be
amenable to therapeutic modulation are numerous
[13,14]. When considering septic AKI as a disease entity
in which hemodynamic compromise of the kidney alone
is no longer the rule, a revision of the “prerenal” AKI
concept must be anticipated. Several assumptions asso-
ciated with the “prerenal azotemia paradigm” will be in
violation of this revised definition [15]. It is not evi-
denced that acute tubular necrosis (ATN) is the histo-
pathological substrate of septic AKI and, above all, it is
not proven that urine tests can discriminate between
functional and structural AKI.
Diagnosis of AKI and potential role of biomarkers
Early recognition of AKI in the ICU setting is crucial.
Indeed, AKI has become a major issue with rising inci-
dence causing more than four million deaths per year
worldwide [16]. Also, the lack of an early and reliable
biomarker for AKI causes significant delay in initiating
appropriate therapy [16]. This is in contrast with the
“biologic revolution” in cardiology, which produced var-
ious markers (including troponin) for early diagnosis of
cardiac damage that enabled early and effective treatment
[17]. In fact, standard evaluation of renal function still
largely depends upon serum creatinine and serum creati-
nine-based formulas, which were primarily designed for
longitudinal assessment of baseline renal function
[18-20]. An accurate diagnosis of AKI is even more pro-
blematic in critically ill patients. The instability of renal
function in this population significantly reduces the
validity of measures based on creatinine assessment
[21,22]. Until recently, studies of AKI used various creati-
nine-based equations designed to evaluate baseline renal
function [23]. This approach is not adequate in the criti-
cally ill. A more accurate and sensitive description of
AKI and a multidimensional AKI classification system
are definitely needed. Basically, such system should grade
AKI severity.
At present, the most widely used classification is the
RIFLE model (acronym for Risk, Injury, Failure, Loss,
End-stage renal disease) [24], proposed by the Acute Dia-
lysis Quality Initiative group. Hoste et al. [25] validated
the RIFLE criteria in critically ill adults, showing that
patients with maximum RIFLE class R, I, and F had hos-
pital mortality rates of respectively 8.8%, 11.4%, and
26.3% [25]. Finally, recognition of AKI before changes in
serum creatinine occur has been and remains an area of
current intensive research. The rationale comes from stu-
dies demonstrating that even small or relative increases
in serum creatinine are associated with increased patient
morbidity and mortality, independently from expected
calculated mortality.
As anticipated, Chertow et al. recently found a nearly
sevenfold increase in the odds of death in patients with
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adjusted for numerous comorbidities [26]. The search
for valuable and early markers for AKI in critically ill
patients must be prioritized because critically ill patients
are dying from and not just “with” AKI, underscoring
that AKI is an independent risk factor for mortality;
indeed, acute kidney injury network (AKIN) was con-
ceived to better tackle this important issue [24,25]. To
date, however, the development of an early marker for
renal dysfunction in the ICU remains elusive [17].
Serum creatinine concentrations and creatinine clear-
ance are unreliable indicators for acute and abrupt
changes in kidney function [27]. Serum creatinine only
comes into play as a marker for decreasing kidney func-
tion after more than 50% of kidney function has been
lost. It is only useful after a steady state has been
reached, which can take considerable time in ICU
patients [28]. Creatinine clearance somewhat better
reflects changes in kidney function. However, loss of
kidney function occurs at a late phase in the process of
cellular kidney damage, which explains why a decrease
in creatinine clearance detects AKI with a delay of many
hours [29].
Human studies have shown that AKI can be prevented
and treated if adequate measures are undertaken shortly
after the initial kidney insult [30]. As such, they stress
the need to obtain an early biomarker of kidney injury
in the ICU for optimization of timely treatment [31].
Biomarkers also may become tools to better differenti-
ate AKI etiology, thus directing more appropriate treat-
ment [32]. An early biomarker might have prognostic
implications, given the immense impact of AKI-asso-
ciated mortality on global disease-related mortality
[33,34]. Unfortunately, all actually studied biomarkers
have insufficient sensitivity to detect AKI in the ICU,
a n dd i a g n o s t i cp o w e rm a yo n l yi n c r e a s ew h e nac o m b i -
nation of various biomarkers is used, including cystatin-
C, Neutrophil gelatinase-associated lipocalin (NGAL) in
the serum and urine, IL-18, and kidney injury molecule
1 (KIM -1) [34-36].
Type of therapy in a general ICU setting
CRRT in ICU patients can be provided as continuous
veno-venous hemodiafiltration (CVVHDF), CVVH, or in
a hybrid form, such as high-volume CVVH. IRRT options
include sustained low-efficiency dialysis (SLED), intermit-
tent hemodialysis (IHD), or others. Much debate is
ongoing about choice of epuration mode (continuous or
intermittent), choice of technique (diffusion or convec-
tion), or eventual combination of techniques (diffusion
on top of convection) [37]. In fact, CVVH, CVVHDF,
and related techniques are more suitable for indications,
such as hemodynamic instability, hepatorenal syndrome,
raised intracranial pressure, and (sub)acute or extreme
fluid overload. Likewise, intermittent therapies have
proper advantages [38,39]. However, many intensivists
are inclined to employ continuous methods, especially in
hemodynamically unstable patients. This attitude gained
more acceptance after publication of a meta-analysis,
which showed less hemodynamic instability and better
control of fluid balance with CRRT [40,41]. Furthermore,
a recent study of the PICARD group showed that CRRT
rather than any intermittent or semi-continuous method
was able to remove extra fluid in severely fluid-over-
loaded AKI patients [42]. Although some groups have
reported no overt problems with IHD in unstable ICU
patients [42-44], most opinion leaders consider CRRT as
the most appropriate therapy in vasopressor-dependant
patients with AKI. This recommendation is supported by
aggregated data of the ATN and RENAL studies, indicat-
ing that vasopressor-dependant ICU patients on CRRT
will less frequently evolve to chronic dialysis than
patients who receive intermittent therapies [45]. The
same opinion leaders also recommend CRRT during the
acute phase of AKI, particularly in patients with severe
hemodynamic instability or when extensive fluid removal
may allow more effective drug therapy [40,42,46]. Admit-
tedly, two recent RCTs did not show superiority of CRRT
to IHD [2,3]. Indeed, the Hemodiafe study [2], comparing
IHD with CVVHDF in ICU patients, showed that both
techniques were comparable in terms of patients’ out-
come. This was confirmed by a subsequent RCT [3].
Only a few, small, randomized and observational studies
did not find a difference between SLED and CRRT
[47,48]. A recent paper that reviewed the data discussed
during the preparation of the most recent KDIGO guide-
lines gave CRRT and SLED the same level of evidence
[49], although there are only very few randomized studies
comparing SLED and CRRT, whereas there are large
numbers of randomized studies that compare IHD and
CRRT. In other words, the level of evidence is much
weaker for SLED. As a consequence, many experts in the
field still recommend CRRT and not SLED in hemodyna-
mically unstable patients [37].
Choosing between diffusion and convection–still an
ongoing dilemma but with light at the end of the tunnel
Diffusion permits removal of small molecules and an
excellent ionic equilibration, whereas convection more
efficiently eliminates middle-large molecules. However,
when a high cut-off membrane is employed, dialysis
techniques also can remove larger molecules, which ren-
ders the difference between convection and diffusion
very artificial [50-52]. To date, no superiority of one
method over the other has been demonstrated in terms
of improved outcome, except for some small studies
that have reported better performance of large pore
membranes [53,54].
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large scale with the newest large pore membranes (e.g.,
SepteX
®;G a m b r o ™) [55]. A new generation of mem-
branes has emerged that specifically focuses on endo-
toxin adsorption (Toraymyxin
®,T o r a y ™ and Oxiris
®,
Gambro™) or immunoadsorption (Prosorba
®,F r e s e -
nius™). Recent studies using these membranes were
promising [56], but larger RCTs are awaited. Addition-
ally, the use of citrate [57] and a larger surface mem-
brane [58] have both been shown to narrow the gap
between diffusion and convection principles for remov-
ing middle-large molecules.
Type of dose provision in septic and non-septic AKI
Two recent, large RCTs provided more insight in the
dosing of fluid exchange. The pivotal study by Ronco et
al. in ICU patients recommended a hemofiltration dose
of 35 ml/kg/h [59].
This association between increasing renal replacement
dose (RRT) and better outcome was further addressed by
two, large, randomized, landmark studies. One study
found better outcome in patients treated by hemodialysis
on a daily base rather than three times per week [60].
Essentially, this study underscored that an IHD session of
4-h duration repeated three times per week was not an
adequate treatment for ICU-acquired AKI. Approximat-
ing the more efficient dosing regimen found by Ronco,
the other study showed that increasing convection dose
and adding dialysis to hemofiltration improved outcome
[61]. However, a recent RCT (acute renal failure trial net-
work (ATN study)) conducted by Palevsky et al. showed
that less intensive therapy (IHD three times per week,
CVVHDF at 20 ml/kg/h, or SLED for unstable patients)
was comparable to intensive therapy (daily hemodialysis
or CVVHDF at 40 ml/kg/h for unstable patients) in
terms of mortality at 90 days [62]. Nonetheless, this
study had several limitations. More than 65% of the
patients already received intermittent therapy before
being allocated to a specific treatment group [63,64].
Intervention also was extremely delayed, which could
have had a negative impact on outcome of the intensive
therapy group [63,64]. Finally, the relatively low rate of
continuous therapy compared with other large, rando-
mized studies may have influenced the renal recovery
rate [45]. A more convincing answer regarding the dose
for non-septic AKI came from the so-called “randomized
evaluation of normal versus augmented levels” (RENAL)
study, which demonstrated no beneficial effect of
CVVHDF at 40 ml/kg/h compared with 25 ml/kg/h [65].
Therefore, current consensus suggests a hemofiltration
dose of 25 ml/kg/h in nonseptic AKI with no additional
benefit from a dose increase. However, some important
issues must be stressed. First, expert opinion imposes
that patients should not be undertreated and should
receive at least 25 ml/kg/h of fluid exchange. In practice,
this implies prescribing 30-35 ml/kg/h to account for
predictable (bags change, nursing...) or unpredictable
(surgery, clotting...) breaks in treatment [4,66]. Second,
the amount of dose to be used in septic AKI remains
questionable; some small, prospective, randomized stu-
dies have shown a beneficial effect of high-dose hemofil-
tration. The multicenter “IVOIRE study” (hIgh Volume
in Intensive care), which compared hemofiltration doses
of 35 ml/kg/h versus 70 ml/kg/h in patients with sepsis-
induced shock, AKI, and multiple organ failure, may set-
tle this debate in the near future. Although patients
included were more severely ill, overall mortality in the
IVOIRE study remains very low (39% at 28 days and 52%
at 90 days) compared with the RENAL study. This may
be due to the earlier start of treatment at the renal injury
level [67]. Awaiting results from this important trial,
35 ml/kg/h should remain the standard dose in septic
AKI, particularly in the presence of shock.
The complex issue of “timing of CRRT” during AKI in ICU
patients
The right time to start RRT is still a topic of debate. The
main reasons are the absence of a clear and consensual
definition of AKI to stratify patients according to the
degree of renal impairment and the difficulty to obtain
homogeneous patient groups for study purposes. The
development of two new classifications, RIFLE and
AKIN, represents a major step forward [68]. Both classifi-
cations alert clinicians of the presence of AKI and allow
early intervention.
Several recent studies and meta-analyses fuelled inter-
est for early start of RRT, but large RCTs about this topic
are still awaited. One RCT regarding timing of hemofil-
tration (defined as the time between ICU admission and
start of therapy) was negative [69]. However, this trial
was insufficiently powered and included a very selective
post-cardiac surgery population. Experts recommend
beginning RRT earlier, particularly in sepsis where AKI is
known to be rapidly progressive. However, a French RCT
[70] showed the opposite and a Belgian study raised con-
cern about a potentially harmful effect of starting RRT
too early [71]. It seems acceptable to start RRT at the
RIFLE injury stage (or AKIN stage 2) in septic AKI, espe-
cially when shock is present, but consensus on this topic
awaits results from large-scale RCTs. Early use of RRT
also may be relevant in patients, mainly pediatric, treated
by extracorporeal membrane oxygenation for severe
acute respiratory distress syndrome (ARDS) [72,73].
Fluid overload definitely plays a role in timing, because
CRRT proved successful in patients without AKI but
refractory to diuretics [72]. On top of this, new compo-
site indices of timing have been proposed (e.g., severity of
organ dysfunction (SOFA score), severity of AKI (RIFLE
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sion, biomarker use, etc.), but their use in daily practice
r e m a i n st ob ee v a l u a t e d[ 7 4 ] .I nt h a tc o n t e x t ,ar e c e n t ,
prospective study [75] and meta-analysis clearly favored
early timing [76].
Anticoagulation during CRRT: is citrate no longer the
Achilles’ heel?
Anticoagulation remains the topic of continuous develop-
ment and research, in particular since the introduction of
citrate and upcoming dedicated machines. Unfractionated
heparin (UFH) remains the most commonly used anticoa-
gulant for RRT worldwide, but citrate and other alterna-
tives become increasingly important. Oudemans van
Straaten et al. compared citrate to low molecular weight
heparin (LMWH) anticoagulation in a predominantly sur-
gical population [77]. Although no difference was found in
terms of efficacy, an unexplained improved outcome was
observed in the citrate-treated patients. In fact, 3-month
mortality (63%) was unexpectedly high in the LMWH
group, whereas outcome in the citrate group (48%)
approached “usual” mortality. Antithrombin must be
taken into consideration when using UFH during RRT,
because it is a mandatory yet often neglected cofactor for
coagulation. Antithrombin activity often is reduced neces-
sitating supplementation in critically ill, particularly septic,
patients [78]. A final issue concerns the replacement fluid.
The composition of new products on the shelf more clo-
sely resembles that of plasma (e.g., by having phosphorus
directly added to the fluid bag) [79], thereby avoiding the
previously observed severe ionic disturbances [80].
New perspectives for medical treatment of septic AKI
With septic AKI seen as an apoptotic-inflammatory AKI,
the administration of caspase inhibitors (CI) gains increas-
ing interest. Indeed, CI ameliorate ischemia-reperfusion
injury in different organs, including the kidneys. However,
it remains uncertain to what extent this protective effect
of caspase inhibition is caused by reduced (intra-renal)
inflammation or by less renal tubular cell loss due to apop-
tosis [7]. In addition to caspase inhibition, the apoptotic
pathway offers many opportunities for therapeutic inter-
ventions that may prevent or reduce renal tubular cell
apoptosis and, as such, renal function impairment. In a rat
model of glycerol induced AKI (Gly-AKI) [81], caspases
were found to participate in inflammation, apoptosis, vaso-
constriction, and finally tubular necrosis. Early caspase
inhibition attenuated these processes and significantly
improved renal function [82]. Apoptosis also occurs in the
kidney during LPS-induced AKI (LPS-I-AKI) [83], but its
relative importance in this condition remains unproven.
Guo and coworkers [83] hypothesized that treatment with
a caspase inhibitor would protect mice from LPS-I-AKI.
Mice, injected with LPS, were either treated with a broad-
spectrum caspase inhibitor or placebo. Caspase inhibition
was found to protect against LPS-I-AKI, not only by pre-
venting apoptotic cell death but also by inhibiting inflam-
mation [83]. The authors concluded that apoptotic kidney
cells may act as a source of local inflammation producing
subsequent non-apoptotic renal injury [83]. Another
r e c e n ts t u d y[ 8 4 ]s h o w e dt h a tp l a s m af r o ms e p t i cb u r n
patients with AKI could initiate pro-apoptotic effects and
in vitro functional alterations of renal tubular cells and
podocytes that correlated wit ht h ed e g r e eo fp r o t e i n u r i a
and renal dysfunction. In this model, additive and even
synergistic effects of sepsis and burn injury were noticed.
Further research for therapeutic interventions is warranted
in several areas such as binding and elimination of endo-
toxin by extracting the source of sepsis, blocking of var-
ious apoptotic pathways, or even extracorporeal removal
of circulating toxic mediators using high volume hemofil-
tration, high permeability hemofiltration and plasma filtra-
tion coupled with adsorption [85]. A recent study showed
that extracorporeal therapy with polymyxin B therapy
reduced the pro-apoptotic activity of plasma of septic
patients on cultured renal cells, providing further evidence
for a preponderant role of apoptosis in the development of
sepsis-related AKI [86]. It seems likely that plasma separa-
tion techniques can prove beneficial in renal injury
through the removal of pro-apoptotic factors and cyto-
kines. In fact, the higher mortality of sepsis-associated AKI
is not linked to intrinsic renal lesions alone but correlates
well with remote sepsis-induced inflammatory tissue
damage [87]. It is known that AKI, and sepsis-induced
AKI in particular, may induce a state of immunoparalysis,
thereby increasing the risk of subsequent infection [88].
Therefore, the inflammatory process accompanying septic
AKI may substantially influence the dose of therapy [89]
and, by removing pro-apoptotic factors, plasma separation
could be positioned more as a preventive than as a treat-
ment measure for AKI [88].
New avenues in the “CRRT armamentarium” for septic
AKI
At first glance, high permeability hemofiltration (HPHF)
or even high-volume hemofiltration (HVHF) seem to be
attractive alternatives to classical CRRT. Removal of
higher molecular weight mediators is greatly enhanced
by HPHF [90]. Since the early 1990s, it has been advo-
cated that reducing cytokine levels in the blood compart-
ment could theoretically lower mortality. Reducing the
unbound cytokine load was logically assumed to limit
remote organ damage, hence reducing overall mortality.
However, recent insight in cytokine pharmacokinetics
shows that this is an oversimplified generalization of a far
more complex process, because it neglects the possible
effects that changes in blood cytokines might have at the
interstitial and tissue level [91]. In this setting, techniques
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are privileged. Such techniques include (very) HVHF as
well as HPHF [92,93], super high flux hemofiltration
(SHFHF), hemadsorption, and coupled plasma filtration
and adsorption (CPFA) [94]. Because the clinical effec-
tiveness of blood purification techniques could not be
explained by a concomitant decline in blood mediator
levels [95], interest shifted to the effects of HVHF at the
interstitial and tissue level. Unfortunately, it is almost
impossible to measure interstitial mediator levels and, as
such, to quantify how HVHF interacts with the immune-
inflammatory pathways to produce the observed signifi-
cant dynamic changes in tissues and interstitium. Indirect
evidence of a link between mediator level and subsequent
tissue damage should consist of their therapeutic removal
to a threshold value at which destructive inflammation is
abated. Furthermore, the mechanism facilitating media-
tor and cytokine flow from the interstitial to the blood
compartment during HVHF is unclear. The use of large
replacement volumes for HVHF could promote and
enhance lymphatic flow from the interstitium to the
blood. Lymphatic flow can increase 20- to 40-fold when
large fluid volumes (3 to 5 l/h) are infused [96]. Thus, the
high fluid volume exchange in HVHF increases lymphatic
flow, which directs mediators and cytokines to the blood
compartment where they are subsequently removed,
whereas HPHF, although able to remove larger amounts
of mediators and cytokines from the blood, lacks the abil-
ity to influence processes outside the blood compart-
ment. Of note is that increasing filter porosity might be a
potentially effective method, because mediators have
higher molecular weights than the cut-off points of con-
ventional hemofilters [97]. In this respect, a recent study
using a high cut-off (60 kilodaltons (kDa)) filter showed
promising results [53]. Appar e n t l y ,t h i si si nc o n t r a s t
with HVHF and derived techniques, which address clear-
ance of molecules below 45 kDa and with plasma filtra-
tion that targets molecules around 900 kDa. It is
imperative to further develop methods that modulate the
mediator spectrum between these two extremes [54].
Whether this technique may cause unwarranted loss of
beneficial nutrients, hormones and drugs (e.g., antibio-
tics) is unclear. Large RCTs applying specifically designed
high cut-off hemofilters are expected to explore this
aspect of HPHF. Potential side-effects due to the unde-
sired loss of vital substances could eventually be circum-
vented by the recently described hybrid techniques, such
as CPFA and cascade hemofiltration (CCHF) [98]. Only
target molecules within a relatively strict range of mole-
cular weight are adsorbed and treated blood is returned
to the patient. Except for one small study regarding safety
[55], no large RCT has compared classic membranes with
membranes exhibiting large pores, such as SepteX
®
(Gambro™). A new generation of membranes has
emerged that focuses on endotoxin adsorption (Toray-
myxin
®;T o r a y ™ or Oxiris
®;G a m b r o ™)o rs p e c i f i c
immuno-adsorption (Prosorba
®;F r e s e n i u s ™). Prelimin-
ary results are promising [56], and future large RCTs are
being prepared. As alluded in recent reviews, a more in-
depth understanding of the mechanisms of blood purifi-
cation removal is needed [99-101]. Finally, the type of
vasopressor used for resuscitation may have an impact
on apoptosis. During well-resuscitated septic shock after
porcine peritonitis, low-dose arginine vasopressin is asso-
ciated with less kidney damage by reducing both tubular
apoptosis and systemic inflammation compared with nor-
adrenaline [102].
Conclusions and perspectives
New insights into the pathophysiology of septic AKI pro-
vide justification for future treatment studies. Exciting
targets of intervention are the caspase cascade and intrar-
enal inflammatory pathways. During the past decade,
hemofiltration has evolved steadily from a pure treatment
for AKI to an important adjunctive therapy for sepsis and
other inflammatory diseases (e.g., acute pancreatitis).
More sophisticated technology along with a better under-
standing of immune-inflammatory pathways will more
appropriately define hemofiltration doses and enhance
efficacy of the devices. Actually, 35 ml/kg/h is considered
to be the standard hemofiltration dose for treatment of
septic AKI. However, in view of the high mortality rate in
septic shock, a higher dose is required as salvage therapy
in this condition. For non-septic-AKI, 25 ml/kg/h is the
rule, but to achieve this goal 30 to 35 ml/kg/h must be
prescribed. More data are eagerly awaited (especially the
complete IVOIRE results) before a definite dose regimen
can be recommended as routine ICU treatment of septic
AKI. In recent years, many RRT modalities have been
studied and developed for use in clinical sepsis. Manipu-
lation of ultrafiltration dose, membrane porosity, mode
of clearance, and combinations of techniques have all
yielded promising findings. Atp r e s e n t ,c o n c l u s i v ee v i -
dence based on well designed, randomized, and con-
trolled trials remains scarce, limiting implementation of
these techniques in daily practice outside a study context.
From the few studies so far, it can be concluded that
optimalization of delivered dose in RRT has a proven
positive effect. An ultrafiltration rate between 35 and
45 ml/kg/h, adjusted for predilution and down time, is
recommended in sepsis. The results of further dose out-
come studies using higher ultrafiltration rates will likely
be the stepping stone to further improvements in daily
clinical practice. In the near future, hybrid techniques
most likely will expand the spectrum of RRT in sepsis.
Recent information from substudies of the IVOIRE pro-
ject suggests that starting treatment for septic AKI
should be closer to rifle grade injury than failure. Large
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knowledge and to decrease ultimately the unacceptably
high mortality rate of ICU patients suffering from AKI.
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